A randomized, double‐blind, placebo‐ and propiverine‐controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder
Authors:
- Yukio HommaYHYukio Homma
- Imidafenacin Study GroupIGImidafenacin Study Group
- 28 April 2009
- journal article
- research article
- Published by Wiley in International Journal of Urology
- Vol. 16 (5) , 499-506
Abstract
Objectives: To compare the efficacy and tolerability of imidafenacin, a novel antimuscarinic agent, with propiverine and a placebo in Japanese patients with overactive bladder (OAB).Methods: Men and women having OAB symptoms were randomized to double‐blind treatment with 0.1 mg of imidafenacin twice daily, 20 mg of propiverine once daily, or a placebo for 12 weeks, and assessed for efficacy and safety.Results: Overall, 781 patients were randomized to imidafenacin (324), propiverine (310), or a placebo (147). After 12 weeks of treatment, a significantly larger reduction in the mean number of incontinence episodes was observed in the imidafenacin group than in the placebo group (P < 0.0001). The non‐inferiority of imidafenacin compared with propiverine was confirmed for the reduction in using incontinence episodes (P = 0.0014, non‐inferiority margin: 14.5%). Imidafenacin was well tolerated. The incidence of adverse events with imidafenacin was significantly lower than with propiverine (P = 0.0101). Dry mouth, the most common adverse event, was significantly more common in the propiverine group than in the imidafenacin group (P = 0.0302). There were no significant increases in either the imidafenacin or placebo group in the mean QTc interval, whereas there was a significant increase in the mean QTc interval in the propiverine group (P < 0.0001), but there were no clinical arrhythmia and clinical arrhythmic events in any of the treatment groups.Conclusions: The novel antimuscarinic agent imidafenacin at a dose of 0.1 mg twice daily was not inferior to propiverine for the reduction of incontinence episodes, and well tolerated for the treatment of OAB symptoms.Keywords
This publication has 11 references indexed in Scilit:
- Long‐term safety, tolerability, and efficacy of the novel anti‐muscarinic agent imidafenacin in Japanese patients with overactive bladderInternational Journal of Urology, 2008
- A randomized, double‐blind, placebo‐controlled phase II dose‐finding study of the novel anti‐muscarinic agent imidafenacin in Japanese patients with overactive bladderInternational Journal of Urology, 2008
- Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacinInternational Urogynecology Journal, 2006
- An epidemiological survey of overactive bladder symptoms in JapanBJU International, 2005
- Drug-Induced Prolongation of the QT IntervalNew England Journal of Medicine, 2004
- Prospective, Randomized, Double-Blind Study of the Efficacy and Tolerability of the Extended-Release Formulations of Oxybutynin and Tolterodine for Overactive Bladder: Results of the OPERA TrialMayo Clinic Proceedings, 2003
- Prevalence and burden of overactive bladder in the United StatesWorld Journal of Urology, 2003
- The standardisation of terminology of lower urinary tract function: Report from the standardisation sub‐committee of the International Continence SocietyNeurourology and Urodynamics, 2002
- How widespread are the symptoms of an overactive bladder and how are they managed? A population‐based prevalence studyBJU International, 2001
- Quality‐of‐life aspects of the overactive bladder and the effect of treatment with tolterodineBJU International, 1999